Biotechnology / Medical Research
Miraca Holdings Inc Announces Merger between Subsidiary and Sub-subsidiary
Miraca Holdings Inc announced that its Tokyo-based wholly owned subsidiary SRL, Inc. will merge with a Tokyo-based wholly owned subsidiary of SRL, effective October 1, 2013. As a result, SRL will be the surviving company and the subsidiary of SRL will be dissolved. The two companies are both engaged in contract clinical test business.
Clavis Pharma ASA Updates on Operational Restructuring; to Cut Jobs
Clavis Pharma ASA announced that the operational restructuring of the Company, following the negative outcome of the CLAVELA Phase III study announced in April 2013, is progressing according to plan. As described in the financial report for the first quarter of 2013, the Company has suspended any further development activities and has taken the necessary steps to minimize the future operating expenditure. All patients have completed treatment in the Company's clinical trials, and the trials have been closed. As part of the restructuring, most of the employees of Clavis Pharma will leave the Company by June 30, 2013. The Board is still in the process of evaluating the strategic options for the Company, and any potential proposals will be communicated in due course. Clavis Pharma will have estimated net cash (cash and cash equivalents, net of any borrowings and other liabilities) of between NOK 35 million and NOK 40 million at the end of 2013. The Company also announced that a more detailed financial update will be given in the second quarter financial report, to be released on August 28, 2012.
4 SC AG Announces Restructuring and Layoffs
4 SC AG announced that due to changes in the personnel structure, mainly concerning aspects of preclinical and early clinical development, as well as in administration restructuring, the Ueberlingen-Bonndorf office will be closed. This will reduce the number of employees from 84 (as at May 31, 2013) by 13% or 15% over the course of 2013.
Markets
- Sectors
- U.S.
- Europe
- Asia
Sector Summary
| Energy |  -0.01% |
| Basic Materials | -0.88% |
| Industrials | -0.61% |
| Cyclical Goods & Services |  +0.03% |
| Non-Cyclical Goods & Services | -0.23% |
| Financials | -0.23% |
| Healthcare | -0.43% |
| Technology | +0.04% |
| Telecoms | +0.08% |
| Utilities | -0.64% |
| DOW | 14,932.41 | -42.55 |
-0.28% |
| S&P 500 | 1,614.08 | -0.88 |
-0.05% |
| NASDAQ | 3,433.40 | -1.09 |
-0.03% |
| TR US Index | 146.52 | -0.13 |
-0.09% |
Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
